In a recent antitrust ruling reversal, Illumina Inc. has announced its intentions to sell Grail Inc. A U.S. appeals court found that Illumina’s $7 billion acquisition of the cancer detection startup contradicted antitrust laws.
Grail, a groundbreaking startup in cancer detection technology space, attracted acquisition interest from Illumina Inc., a leader in DNA sequencing technology. The $7 billion acquisition would have promised great advancements in cancer detection and research. But this prospective partnership triggered antitrust scrutiny considering both companies’ prominence within their industry sectors.
The U.S. appeals court, reviewing this case, found that this acquisition could potentially curb competition in the multi-cancer early detection (MCED) test market. With their ruling, the court has put a halt on the merger.
Following this legal defeat, Illumina Inc. has decided to sell Grail Inc., to conform with the judicial decision. This prospective sale indicates the growing influence of antitrust law on high-stakes corporate acquisitions, especially within competitive tech sectors.
For further information, I encourage you to dive into the original article from Bloomberg Law here.